Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cloudbreak PharmaHKSE:02592 +0.83%11 Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,194 Biotechnology companies, Cloudbreak Pharma ranks worse than 83752.01% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cloudbreak Pharma's annualized net income for the quarter that ended in Dec. 2025 was HK$-1,133.60 Mil. Cloudbreak Pharma's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$-1,066.50 Mil. Therefore, Cloudbreak Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Cloudbreak Pharma's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02592's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -43.13 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cloudbreak Pharma Return-on-Tangible-Equity Related Terms
Cloudbreak Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cloudbreak Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02592 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Cloudbreak Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cloudbreak Pharma Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cloudbreak Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cloudbreak Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Cloudbreak Pharma (HKSE:02592) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cloudbreak Pharma and its competitors. According to the industry distribution chart, Cloudbreak Pharma ranks #999999 out of 1194 companies in the Biotechnology industry.
Is Cloudbreak Pharma's Return-on-Tangible-Equity too high?
Cloudbreak Pharma's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Cloudbreak Pharma ranks #999999 out of 1194 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cloudbreak Pharma ranks #999999 out of 1194 companies for Return-on-Tangible-Equity. This places Cloudbreak Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score
Get the complete analysis for HKSE:02592
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02592 has been successfully added to your 
